Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.

DPH | IL

Overview

Corporate Details

ISIN(s):
US2434351043
LEI:
213800J4UVB5OWG8VX82
Country:
United Kingdom
Address:
24 CHESHIRE AVENUE, CW9 7UA NORTHWICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dechra Pharmaceuticals PLC is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacture, marketing, and sales of high-quality products designed to improve animal health and welfare. Its portfolio includes a range of drugs and therapies for the prevention, diagnosis, and treatment of conditions in animals, with a focus on companion animals like dogs, cats, and horses. Dechra markets its products exclusively to veterinarians worldwide, positioning itself as a dedicated partner to the profession. The company also provides educational support through resources like the Dechra Academy to help veterinary professionals stay current with industry advancements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-23 17:41
Major Shareholding Notification
Holding(s) in Company
English 23.4 KB
2024-01-18 16:14
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2024-01-18 11:11
Major Shareholding Notification
Holding(s) in Company
English 26.8 KB
2024-01-17 15:01
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-17 13:01
Delisting Announcement
Holding(s) in Company
English 51.4 KB
2024-01-17 13:00
Major Shareholding Notification
Holding(s) in Company
English 54.9 KB
2024-01-17 12:16
Major Shareholding Notification
Holding(s) in Company
English 29.1 KB
2024-01-17 09:15
Delisting Announcement
Cancellation of listing and admission to trading
English 24.9 KB
2024-01-17 08:30
Major Shareholding Notification
Holding(s) in Company
English 21.6 KB
2024-01-16 17:54
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2024-01-16 16:25
Major Shareholding Notification
Form 8.3 - Dechra Pharmaceuticals plc
English 46.1 KB
2024-01-16 15:43
Major Shareholding Notification
Holding(s) in Company
English 31.2 KB
2024-01-16 13:04
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-16 11:15
AGM Information
Scheme of Arrangement becomes Effective
English 45.8 KB
2024-01-16 10:00
Major Shareholding Notification
Holding(s) in Company
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Dechra Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dechra Pharmaceuticals PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dechra Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA

Talk to a Data Expert

Have a question? We'll get back to you promptly.